NATALIE MARTIN: Open Payments
NPI 1194291336 · BROOKLAND, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$705 in 50 payments from 12 companies in 2025. Trend: 2023 $413 · 2024 $806 · 2025 $705
Food & beverage: $705
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $178 |
| PFIZER INC. | 12 | $169 |
| Novo Nordisk Inc | 4 | $81 |
| AstraZeneca Pharmaceuticals LP | 4 | $64 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 4 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Alexion Pharmaceuticals, Inc. | 1 | $21 |
Products named: UBRELVY, NURTEC ODT, Ozempic, ELIQUIS, AIRSUPRA, Auvelity, VOQUEZNA, CAPLYTA.
Industry payments across AR — which companies pay providers there.
